Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib to Enable Partial Nephrectomy in RCC
NCT01158521Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jun 2010
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in clear cell renal cell carcinoma (ccRCC), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Number of Participants Who Could Undergo Partial Nephrectomy After Pazopanib Therapy. Started Jun 2010; status: completed.
02
Drugs
pazopanib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT01158521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01158521.